The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

In this MEDtalk from ESMO 2024, Dr Ingrid Dyvik from Oslo University Hospital, Norway, presents findings from the IMPRESS-Norway trial. This trial evaluates the efficacy of anti-cancer drugs in new indications. Dyvik highlights the role of circulating tumour DNA (ctDNA) in precision oncology.